Pfizer has decided to leave the Biotechnology Innovation Organization, dealing a blow to the biopharma trade group.

Scientists developed a way to analyze the varying rates at which organs age using the distinct proteins that those organs produce and shed into the blood.

A bold idea for how to pay for weight loss drugs for everyone who needs them — and save Medicare at the same time.

A new study found Pap smears stored in a hospital could detect ovarian cancer tumors as much as nine years before the women were actually diagnosed.

The booming obesity market is attracting another player, as Roche plans to acquire Carmot Therapeutics and its weight loss drug candidates.

Pfizer is stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial.

AbbVie will pay $10 billion for Immunogen, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

The FDA is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma.

Hevolution, a Saudi investment firm focused on aging science, is launching an incubator that will bring together experts from the scientific community, pharma, and biotech VCs.

Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover the drug, I have met with Alzheimer’s patients and their loved ones who are anxious to know whether they may benefit from this new treatment. They com

A growing number of state and local governments across the U.S. are suing insulin makers and PBMs over claims they conspired to illegally drive up prices.

Bioscience job postings have dropped from around 19,000 in February 2022 to 10,000 in October 2023.

MedTech Innovator is creating a vibrant community of innovators, injecting a youthful spirit into a somewhat bloated, stodgy industry.

The Texas attorney general is suing Pfizer over allegedly selling ineffective ADHD medicines to the state's Medicaid program.

The U.K. and the pharma industry reached a deal on a five-year plan outlining how the National Health Service pays for drugs.

A FDA advisory panel urged Acrotech Biopharma to accelerate the release of trial data that could confirm benefits of its blood cancer drugs.

U.K. regulators approved a CRISPR-based medicine to treat sickle cell disease and beta thalassemia, ushering in a new era of genetic therapy.

The seismic shift in researchers from academic to biotech labs is already having a detrimental impact on basic research.

The German drug regulator is considering an export ban on Novo Nordisk's diabetes drug Ozempic as European health systems face a shortage.

The AMA called on insurance companies, employers, and government programs to cover obesity treatments.

Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark trial, affirming it offers health benefits beyond weight loss.

Patients loved Carbon Health's telehealth-based program for managing diabetes. That couldn't save it.

Novo Nordisk announced a plan to spend a whopping $6 billion to expand its manufacturing capacity at its main production site in Denmark.

Amazon Prime members have a new offer in addition to the usual delivery and streaming services: Access to One Medical, the Amazon-owned primary care company. Members have the option, announced Wednesday, to pay an additional $9 per month, or $99 per

Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, for which it will be sold as Zepbound.

The FTC is challenging more than 100 patents on brand-name medicines, saying drug companies improperly or inaccurately listed them on a U.S. registry.

The PATCH Act’s recently implemented approach to securing medical devices actually gives malicious actors a blueprint.

Vertex and a U.K. government agency are at odds again over the value of life-saving cystic fibrosis medicines.